Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.34 |
| ▸ | MTTP | P55157 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566409 | 0.72 | S1PR1 (0.58) | SLC13A5POLBRXFP1CNR2S1PR1 | |
| SCHEMBL566609 | 0.68 | S1PR1 (0.61) | S1PR1S1PR3 | |
| SCHEMBL566392 | 0.64 | HTT (0.36) | CNR2S1PR1S1PR3 | |
| SCHEMBL564883 | 0.64 | CD274 (0.45) | EPHX2S1PR1 | |
| SCHEMBL566288 | 0.63 | S1PR1 (0.60) | S1PR1S1PR3 | |
| SCHEMBL566524 | 0.63 | S1PR1 (0.43) | S1PR1 | |
| SCHEMBL575036 | 0.62 | S1PR1 (0.49) | S1PR1 | |
| SCHEMBL3909426 | 0.62 | DHODH (0.49) | POLBRXFP1S1PR1S1PR3 | |
| SCHEMBL566357 | 0.62 | THRB (0.45) | POLB | |
| SCHEMBL13380526 | 0.62 | S1PR1 (0.39) | SLC13A5EPHX2CNR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181182-B2 | S1P receptors modulators | AKAAL PHARMA PTY LTD (AU) | 2015-11-10 | — | — | US | disclosed |
| US-20120034270-A1 | S1P Receptors Modulators | AKAAL PHARMA PTY LTD (AU) | 2012-02-09 | — | — | US | disclosed |
| EP-2344446-A1 | S1P RECEPTORS MODULATORS | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010042998-A1 | S1P RECEPTORS MODULATORS | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034270-A1 | S1P Receptors Modulators | S1PR1, S1PR5, S1PR3 | SLC13A5 4238/4885POLB 4275/4885RXFP1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.